Temozolomide is under clinical development by Orphelia Pharma and currently in Phase I for Pediatric Cancer. According to GlobalData, Phase I drugs for Pediatric Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Temozolomide LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Temozolomide overview
Temozolomide (ORP-005) is under development for the treatment of pediatric cancers including refractory medulloblastoma, rhabdomyosarcoma, neuroblastoma, ewing sarcoma, glioblastoma multiforme, anaplastic astrocytoma, malignant glioma and neuroblastoma. The drug candidate is administered by oral route as a suspension. It is a taste masked formulation coupled with a dispensing device to improve administration and compliance in infants and children. It acts by targeting DNA synthesis.
Orphelia Pharma overview
Orphelia Pharma is a pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. The company is headquartered in Paris, France.
For a complete picture of Temozolomide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
